Boston Scientific/Medinol
This article was originally published in The Gray Sheet
Executive Summary
Letter purporting to terminate exclusive, worldwide NIR coronary stent supply agreement with Boston Scientific is "improper and invalid," Boston Scientific says in a March 1 release. Medinol alleges breaches of the supply agreement, which Boston Scientific disputes. While the parties remain embroiled in litigation in New York and Israel with respect to the supply agreement and management of Medinol, Boston Scientific says it will challenge the latest action and "considers the supply agreement to be in full force and effect"...